Table 1 Strategies for MDR-TB control in the China-Gates TB programme Phase II

• MDR-TB detection: All smear or culture positive patients are tested for drug susceptibility using rapid molecular test

• Referral: County TB designated hospitals are required to refer all MDR-TB patients (Rifampicin resistant inclusive) to city TB designated hospital for diagnosis and treatment

• Health insurance benefits: The reimbursement rate should be 90 % for MDR-TB treatment

• MDR-TB treatment: All MDR-TB (Rifampicin resistant inclusive) patients are treated with standard second line TB regimen and tailed regimen based on tested degree of drugs resistance

• Patient management: 1) Staffs in local CDC and primary health facilities are responsible for MDR-TB patients management for 24 months; 2) MDR-TB patients management information shared between TB designated hospitals and CDCs without barriers

• Transportation subsidy for patients through grant from local Civil Affairs Bureau

• Case-based payment for the full course of MDR-TB treatment